Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Lancet (London, England)·2026
Same author

Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis.

Transplantation and cellular therapy·2026
Same author

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.

Blood·2026
Same author

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.

The Lancet. Oncology·2026
Same author

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia.

Expert review of hematology·2025

相关实验视频

Updated: Jul 9, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.6K

化学抗原受体T细胞治疗

Cale Burge1,2, Vinay Vanguru1,2, Phoebe Joy Ho1,2

  • 1Royal Prince Alfred Hospital, Sydney.

Australian prescriber
|December 6, 2023
PubMed
概括

化学抗原受体T细胞疗法为某些血液癌症提供了新的希望,改善了缓解率. 虽然有效,但潜在的并发症,如细胞因子释放综合征和神经毒性需要谨慎管理.

关键词:
在B细胞淋巴瘤.急性淋巴细胞白血病急性淋巴细胞白血病这样一来,Axicabtagene ciloleucelucel将成为一个可靠的替代品.仿制性抗原受体的仿制性抗原受体这是一个很小的小小的小小的小小的小小的小小的小小的小小的小小的小小的小小的小小的小小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的小的

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K

相关实验视频

Last Updated: Jul 9, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.6K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.1K

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 细胞疗法细胞疗法

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法在治疗血液恶性瘤方面取得了重大进展.
  • 卡尔T细胞是基因工程的淋巴细胞,旨在增强宿主免疫系统向癌细胞的能力.

研究的目的:

  • 审查CAR T细胞治疗复发性或耐火性扩散性大B细胞淋巴瘤和急性淋巴细胞白血病的疗效和安全性.
  • 讨论CAR T细胞疗法在其他血液和固体器官恶性瘤中的潜力.

主要方法:

  • 来自患者的T细胞被采集出来,被基因改造以表达CARs,体外扩展,并重新注入.
  • 该研究涉及对现有临床数据和结果的审查.

主要成果:

  • 在特定的B细胞淋巴瘤和白血病中,CAR T细胞疗法显示增加了完全反应率和长期缓解的潜力.
  • 早期的研究表明,在其他癌症中也有希望,包括地幔细胞淋巴瘤,多发性骨髓瘤和多形质母细胞瘤.

结论:

  • 卡尔T细胞疗法是复发/耐药B细胞恶性瘤的有前途的治疗方式,提供了更好的结果.
  • 短期毒性的管理,如细胞因子释放综合征和免疫效应细胞相关的神经毒性综合征,对于患者的安全至关重要.